In patients with platinum-refractory R/M HNSCC, CPS status is not used and PD-1 inhibitors pembrolizumab and nivolumab may be offered first-line to all patients with recurrent, unresectable, or metastatic disease without a surgical or radiotherapeutic alternative, regardless of CPS status. Here, PDCD1 is linked to head and neck squamous cell carcinoma.